{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:30:38Z","timestamp":1783517438635,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T00:00:00Z","timestamp":1413158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep06605","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T09:13:54Z","timestamp":1413191634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discriminative stimulus effects of the novel imidazoline I2 receptor ligand CR4056 in rats"],"prefix":"10.1038","volume":"4","author":[{"given":"Yanyan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,13]]},"reference":[{"key":"BFsrep06605_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0165-6147(96)81564-1","volume":"17","author":"A Parini","year":"1996","unstructured":"Parini, A., Moudanos, C. G., Pizzinat, N. & Lanier, S. M. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. 17, 13\u201316 (1996).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFsrep06605_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","volume":"19","author":"RM Eglen","year":"1998","unstructured":"Eglen, R. M. et al. \u2018Seeing through a glass darkly\u2019: casting light on imidazoline \u2018I\u2019 sites. Trends Pharmacol Sci 19, 381\u2013390 (1998).","journal-title":"Trends Pharmacol Sci"},{"key":"BFsrep06605_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/bph.12555","volume":"171","author":"JX Li","year":"2014","unstructured":"Li, J. X., Thorn, D. A., Qiu, Y., Peng, B. W. & Zhang, Y. Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain. Br J Pharmacol 171, 1580\u20131590 (2014).","journal-title":"Br J Pharmacol"},{"key":"BFsrep06605_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","volume":"658","author":"JX Li","year":"2011","unstructured":"Li, J. X. & Zhang, Y. Imidazoline I2 receptors: target for new analgesics? Eur J Pharmacol 658, 49\u201356 (2011).","journal-title":"Eur J Pharmacol"},{"key":"BFsrep06605_CR5","first-page":"111","volume":"4","author":"F Ferrari","year":"2011","unstructured":"Ferrari, F. et al. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J. Pain Research 4, 111\u2013125 (2011).","journal-title":"J. Pain Research"},{"key":"BFsrep06605_CR6","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1111\/bph.12728","volume":"171","author":"M Lanza","year":"2014","unstructured":"Lanza, M., Ferrari, F., Menghetti, I., Tremolada, D. & Caselli, G. Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats. Br. J. Pharmacol. 171, 3693\u20133701 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"BFsrep06605_CR7","first-page":"151","volume":"5","author":"C Meregalli","year":"2012","unstructured":"Meregalli, C. et al. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J. Pain Research 5, 151\u2013167 (2012).","journal-title":"J. Pain Research"},{"key":"BFsrep06605_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1749-6632.1999.tb09344.x","volume":"881","author":"AL Hudson","year":"1999","unstructured":"Hudson, A. L. et al. Novel selective compounds for the investigation of imidazoline receptors. Ann. New York Acad. Sci. 881, 81\u201391 (1999).","journal-title":"Ann. New York Acad. Sci."},{"key":"BFsrep06605_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/j.1476-5381.1995.tb16656.x","volume":"116","author":"CM Brown","year":"1995","unstructured":"Brown, C. M. et al. RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Br. J. Pharmacol. 116, 1737\u20131744 (1995).","journal-title":"Br. J. Pharmacol."},{"key":"BFsrep06605_CR10","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1021\/jm800400k","volume":"51","author":"F Gentili","year":"2008","unstructured":"Gentili, F. et al. Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions. J. Med. Chem. 51, 5130\u20135134 (2008).","journal-title":"J. Med. Chem."},{"key":"BFsrep06605_CR11","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1111\/j.1476-5381.2012.01894.x","volume":"166","author":"DA Thorn","year":"2012","unstructured":"Thorn, D. A., An, X. F., Zhang, Y., Pigini, M. & Li, J. X. Characterization of the hypothermic effects of imidazoline I(2) receptor agonists in rats. Br. J. Pharmacol. 166, 1936\u20131945 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"BFsrep06605_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0091-3057(03)00136-9","volume":"75","author":"N MacInnes","year":"2003","unstructured":"MacInnes, N. & Handley, S. L. Potential serotonergic and noradrenergic involvement in the discriminative stimulus effects of the selective imidazoline I2-site ligand 2-BFI. Pharmacol. Biochem. Behav. 75, 427\u2013433 (2003).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"BFsrep06605_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/sj.bjp.0704579","volume":"135","author":"N MacInnes","year":"2002","unstructured":"MacInnes, N. & Handley, S. L. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br. J. Pharmacol. 135, 1227\u20131234 (2002).","journal-title":"Br. J. Pharmacol."},{"key":"BFsrep06605_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/026988119601000403","volume":"10","author":"S Jordan","year":"1996","unstructured":"Jordan, S., Jackson, H. C., Nutt, D. J. & Handley, S. L. Discriminative stimulus produced by the imidazoline I2 site ligand, 2 -BFI. J. Psychopharmacology 10, 273\u2013278 (1996).","journal-title":"J. Psychopharmacology"},{"key":"BFsrep06605_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0968-0896(97)00009-6","volume":"5","author":"M Pigini","year":"1997","unstructured":"Pigini, M. et al. Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem. 5, 833\u2013841 (1997).","journal-title":"Bioorg. Med. Chem."},{"key":"BFsrep06605_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2006.09.031","volume":"553","author":"F Gentili","year":"2006","unstructured":"Gentili, F. et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur. J. Pharmacol. 553, 73\u201381 (2006).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep06605_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev.pa.36.040196.002455","volume":"36","author":"S Regunathan","year":"1996","unstructured":"Regunathan, S. & Reis, D. J. Imidazoline receptors and their endogenous ligands. Ann. Review Pharmacol. Toxicol. 36, 511\u2013544 (1996).","journal-title":"Ann. Review Pharmacol. Toxicol."},{"key":"BFsrep06605_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejphar.2013.09.016","volume":"718","author":"JW Min","year":"2013","unstructured":"Min, J. W., Peng, B. W., He, X., Zhang, Y. & Li, J. X. Gender difference in epileptogenic effects of 2-BFI and BU224 in mice. Eur. J. Pharmacol. 718, 81\u201386 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep06605_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejphar.2011.07.041","volume":"669","author":"JX Li","year":"2011","unstructured":"Li, J. X., Zhang, Y. & Winter, J. C. Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I(2) receptor ligands. Eur. J. Pharmacol. 669, 59\u201365 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep06605_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejphar.2011.09.173","volume":"670","author":"DA Thorn","year":"2011","unstructured":"Thorn, D. A., Zhang, Y., Peng, B. W., Winter, J. C. & Li, J. X. Effects of imidazoline I(2) receptor ligands on morphine- and tramadol-induced antinociception in rats. Eur. J. Pharmacol. 670, 435\u2013440 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep06605_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/sj.bjp.0703294","volume":"130","author":"P Sanchez-Blazquez","year":"2000","unstructured":"Sanchez-Blazquez, P., Boronat, M. A., Olmos, G., Garcia-Sevilla, J. A. & Garzon, J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol. 130, 146\u2013152 (2000).","journal-title":"Br. J. Pharmacol."},{"key":"BFsrep06605_CR22","first-page":"182846","volume":"2014","author":"MF Chen","year":"2014","unstructured":"Chen, M. F. et al. Characterization of imidazoline receptors in blood vessels for the development of antihypertensive agents. BioMed Res. Intl. 2014, 182846 (2014).","journal-title":"BioMed Res. Intl."},{"key":"BFsrep06605_CR23","first-page":"359","volume":"45","author":"TT Yang","year":"2013","unstructured":"Yang, T. T. et al. Mediation of AMP kinase in the increase of glucose uptake in L6 cells induced by activation of imidazoline I-2 receptors. Hormone Metab. Res. 45, 359\u2013363 (2013).","journal-title":"Hormone Metab. Res."},{"key":"BFsrep06605_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1749-6632.1995.tb32397.x","volume":"763","author":"DJ Nutt","year":"1995","unstructured":"Nutt, D. J. et al. Functional studies of specific imidazoline-2 receptor ligands. Ann. New York Acad. Sci. 763, 125\u2013139 (1995).","journal-title":"Ann. New York Acad. Sci."},{"key":"BFsrep06605_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1749-6632.1999.tb09336.x","volume":"881","author":"PV Escriba","year":"1999","unstructured":"Escriba, P. V., Ozaita, A. & Garcia-Sevilla, J. A. Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Ann. New York Acad. Sci. 881, 8\u201325 (1999).","journal-title":"Ann. New York Acad. Sci."},{"key":"BFsrep06605_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.brainres.2009.04.044","volume":"1279","author":"A Kimura","year":"2009","unstructured":"Kimura, A. et al. Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res. 1279, 21\u201328 (2009).","journal-title":"Brain Res."},{"key":"BFsrep06605_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejphar.2012.10.037","volume":"698","author":"JX Li","year":"2013","unstructured":"Li, J. X., Thorn, D. A. & Jin, C. The GPR88 receptor agonist 2-PCCA does not alter the behavioral effects of methamphetamine in rats. Eur. J. Pharmacol. 698, 272\u2013277 (2013).","journal-title":"Eur. J. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep06605.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep06605","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep06605.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:35:23Z","timestamp":1672986923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep06605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,13]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep06605"],"URL":"https:\/\/doi.org\/10.1038\/srep06605","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,13]]},"assertion":[{"value":"7 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6605"}}